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Abstract Spinal cord injuries (SCI) can result in devastat-
ing paralysis, for which there is currently no robustly
efficacious neuroprotective/neuroregenerative treatment.
When the spinal cord is subjected to a traumatic injury,
the local vasculature is disrupted and the blood–spinal cord
barrier is compromised. Subsequent inflammation and
ischemia may then contribute to further secondary damage,
exacerbating neurological deficits. Therefore, understand-
ing the vascular response to SCI and the molecular
elements that regulate angiogenesis has considerable rele-
vance from a therapeutic standpoint. In this paper, we
review the nature of vascular damage after traumatic
SCI and what is known about the role that angiogenic
proteins—angiopoietin 1 (Ang1), angiopoietin 2 (Ang2) and
angiogenin—mayplayinthesubsequentresponse.Tothis,we
add recent work that we have conducted in measuring these
proteinsinthe cerebrospinal fluid(CSF)andserum after acute
SCI in human patients. Intrathecal catheters were installed in
15 acute SCI patients within 48 h of injury. CSF and serum
samples were collected over the following 3–5 days and
analysed for Ang1, Ang2 and angiogenin protein levels using
a standard ELISA technique. This represents the first
description of the endogenous expression of these proteins
in an acute human SCI setting.
Keywords Spinal cord injury.Angiogenesis.Blood–spinal
cord barrier.Angiopoietin.Angiogenin
Introduction
Each year, over 10,000 North Americans suffer acute and
permanent paralysis after sustaining a traumatic spinal cord
injury (SCI) [46]. Not only is an SCI one of the most
physically disabling and psychologically devastating
traumas that an individual can survive, the socioeconomic
burden is enormous. Estimates of the annual medical and
rehabilitative expenses are in the $1 million range for
individuals with high cervical cord paralysis [176]. Whilst
historically this has been an injury of the youth, an ageing
population prone to suffering cervical cord injuries after
falls has altered the demographics of SCI, with a second
peak of traumatic SCI appearing in the elderly population
aged 65 and above [191].
The poor neurologic prognosis for SCI has prompted the
development of a plethora of therapeutic strategies, many of
whichhaveshownpromiseinthelaboratorysetting[122, 123,
185]. A handful of these have been evaluated in human
clinical trials [78], but unfortunately, to date, none has
proven to be convincingly efficacious at improving neuro-
logic function for SCI patients [146]. Methylprednisolone
remains the most extensively studied pharmacologic agent
used for the treatment of acute SCI. However, mounting
criticism around the execution and interpretation of data
obtained from three landmark clinical trials (NASCIS I/II/III)
has prompted many clinicians to abandon this drug, although
it remains a ‘treatment option’ for acute SCI.
It has long been understood that when the spinal cord is
injured (in, for example, a motor vehicle accident), local
mechanical forces disrupt the complex vascular and cellular
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completely. This mechanical ‘primary injury’ is rapidly
followed by an expanding cascade of ‘secondary damage’
mediated by pathophysiological mechanisms including
ischemia, excitotoxicity, inflammation and oxidative stress
(for review, see [120, 161]). Attenuating these mechanisms
to minimize secondary damage and afford ‘neuroprotection’
to regions of the spinal cord that have escaped the primary
injury remains a principal therapeutic strategy.
This highlights the fundamental need to understand the
pathophysiology of the secondary spinal cord damage that
rapidly follows the primary injury. It has become evident
from a vast body of literature in rodent models of SCI that
the processes that mediate secondary injury are extremely
complex. Our focus in this review will be on one aspect of
secondary injury after SCI: The damage to local vascula-
ture, its reparative response and the role that angiopoietins
1 (Ang1) and 2 (Ang2) and angiogenin may play in
mediating this response.
Vascular Supply of the Spinal Cord
In humans, perfusion of the thoracic spinal cord is largely
dependent on the arterial supply from the aorta [135].
Segmental radiculomedullary arteries feed the anterior and
posterior spinal arteries, which are the main circumferential
arteries outside the cord parenchyma (known as ‘extrinsic’
arteries) [21, 75, 188–190]. These give rise to ‘intrinsic
arteries’ which include the central arteries as well as the pial
plexus, which arborize into intramedullary arterioles before
ending as terminal capillary beds. The intrinsic arteries
reside within the spinal cord parenchyma and can be
separated into two discrete circuits [21, 75, 188–190].
These circuits flow in opposite directions, creating a
watershed region where terminal capillary beds of the two
circuits overlap. The ‘centrifugal circuit’ is fed by the
anterior spinal artery and supplies the central two thirds of
spinal cord capillaries, including the dense capillary net-
works which support spinal grey matter and the inner
regions of white matter [190]. The ‘centripetal circuit’ is
fed by the posterior spinal artery as well as the many
anastomoses arising from the anterior and posterior spinal
arteries [190]. Vessels of this circuit supply much of the
posterior (dorsal) spinal cord as well as most of the
peripheral white matter and the dorsal grey horns [75,
188–190].
The centrifugal and centripetal vascular circuits meet in a
complex network of terminal capillary beds. It is important
to note that there is an approximately 5-fold increase in the
density of such capillary beds which serve the grey matter
as compared to that of the white matter [190]. This is likely
attributable to the greater metabolic demands of cell bodies
in the grey matter compared to axons of the white matter
[188].
Vascular Injury After Spinal Cord Injury
It has been recognized for many years that trauma to the
spinal cord disrupts its local vasculature. As early as 1914,
Allen described the development of haemorrhage and
oedema within the spinal cord after experimental SCI in
dogs [5]. The primary insult causes immediate vascular
disruptions at the injury epicentre [5, 26, 64, 89, 204]. This
damage primarily affects the microvasculature, resulting in
petechial haemorrhage observed at the injury epicentre
immediately after injury [26, 42]. This haemorrhage starts
near the central canal and is initially confined to the
capillaries of the grey matter at 1 h post-injury, then spreads
to the white matter by 2 h post-injury [5, 13, 147]. Most of
the necrotic damage to endothelial cells occur during the
first 24 h post-injury and can largely be attributed to the
initial mechanical insult [26]. Further, endothelial cell loss
after the first day, manifested as a decrease in intact blood
vessel staining by rat endothelial cell antigen-1 [25, 130]
and platelet–endothelial cell adhesion molecule (PECAM)
[194], is attributed to apoptosis triggered by ischemia [26].
It has also been suggested that there is substantial oncotic
endothelial cell death as a result of ionic imbalance due to
the sustained activation of Trpm4 channels after SCI [60,
175]. Vessel density continues to decrease during the first
2 days, with little or no observable vessels at the injury
epicentre [25, 194].
Angiogenesis is the process of blood vessel growth from
existing vessels. This is distinct from the process of
vasculogenesis, which is the de novo formation of blood
vessels from mesenchymal tissue. After SCI, angiogenesis,
presumably sprouting from vessels that are spared from the
primary insult, starts 3 [42] to 4 days post-injury [25] and is
observed for up to 1 week post-injury [25]. Revasculariza-
tion to an extent that is comparable to control values [194]
or even up 540% [42] in vessel density has been reported at
7 days post-injury [42, 194]. However, these neovessels,
which grow longitudinally through the injury epicentre
[25], are not associated with neurons, astrocytes [25]o r
pericytes [61]. The restoration of Glut-1 transporters, which
are responsible for transporting a constant supply of
glucose across the blood–brain barrier (BBB) to metabol-
ically fragile CNS neurons, has not been observed until the
2-week time point [194]. This suggests that although there
is significant angiogenic growth during the early post-injury
phases of SCI, these neovessels may not be fully functional,
given the important role that astrocytes and pericytes have
on vascular function within the nervous system. Perhaps as
a consequence of the lack of integration of these neovessels
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pruning of these vessels at 2 weeks post-injury [25]. There
is a more prolonged phase of angiogenesis from 4 weeks to
2 months post-injury, along with significant deposition of
new basal lamina [130]. This further indicates that
maturation and organization of neovessels occur after the
first angiogenic phase and that much of the endothelial cell
sprouts are pruned away based on the metabolic demand of
the local area, with only a portion remaining to become
stable, functionally integrated blood vessels.
The disruption of local microvasculature reduces perfu-
sion of the remaining cord parenchyma [17, 63, 170].
Neurons have high metabolic requirements and are thus
extremely vulnerable to reductions in perfusion and
resultant periods of ischemia. This may be compounded
by the loss of auto-regulatory mechanisms [65, 66, 170]
and systemic hypotension, which is common in acute SCI
patients, as the result of hypovolemic and/or neurogenic
shock [22, 66, 170, 171, 183]. At rest, neurons require more
than three times the energy usage (in terms of ATP) than
glial cells [10]. This difference increases to more than five
times per second in a neuron that is generating action
potentials [10]. This highlights the importance that ische-
mia holds in the neurological deterioration of SCI patients
after the initial insult.
The Blood–CNS Barrier
It is important to realize that the consequences of the
aforementioned microvascular damage are not limited to
endothelial cell death and the loss of perfusion but also
involves the breakdown of the blood–spinal cord barrier
(BSCB). Anatomically, the blood–CNS barrier is man-
ifested by several components of the capillary wall
including endothelial cells, pericytes, astrocytes and the
extracellular matrix. Endothelial cells in the CNS are
overlapping, with tight junctions sealing paracellular
spaces [23], no fenestrations [23, 47, 158] and minimal
pinocytosis [169]. They also have an increased mitochon-
drial content, presumably to support transporters such as
Glut-1 for glucose transport across this barrier [149].
Molecularly, the junctional complexes between adjacent
endothelial cells are made of a combination of adherens
and tight junctions. Adherens junctions are found in all
vessel walls. They mediate the adherence of endothelial
cells to one another by linking the actin cytoskeletons of
adjacent cells [166]. Tight junctions are only found in
blood–CNS interfaces. They are comprised of a complex
of transmembrane proteins including junctional adhesion
molecules [134], occludins [54] and claudins [56], which
span the entire intercellular cleft, and intracellular acces-
sory proteins including the zonula occludens [177], which
link the transmembrane components to the cytoskeleton
[45, 55].
Pericytes surround the endothelial cells and have a
significant role in regulating BBB properties [9], as well
as influencing endothelial cell proliferation, migration and
differentiation [9, 156]. Pericytes also mediate proper
orientation and positioning of astrocytic foot processes
around vessel walls [9]. The basal lamina, made of
proteoglycan and laminin components, wraps around the
layer of endothelial cells and pericytes, providing physical
support for the vessel wall through interaction with other
extracellular matrix components [97]. The basal lamina can
also stimulate the expression of tight junction-related
proteins to help maintain BBB function [163]. Astrocytic
foot processes are juxtaposed against the basal lamina-
covered capillaries. They have a critical role in the
formation and maintenance of the BBB [1, 79, 85, 100,
137] and can modulate endothelial permeability via the
secretion of chemical substances. Together, these compo-
nents constitute a functional neurovascular unit—another
example of how the vascular and nervous systems are
physiologically linked.
Whilst the BSCB has slight structural and physiological
differences from the BBB (some of which are highlighted
in [14]), functionally the two play similar roles in protecting
the CNS environment from the systemic circulation. There
are a number of important aspects to this function, which
include controlling ionic balance, regulating nutrient trans-
port and restricting the passage of neurotoxic molecules and
inflammatory cells.
The perception that the CNS is an immune privileged
zone was first hypothesized in 1925 by Billingham and
Boswell, who reported the lack of leukocyte infiltration
in the brain [20]. Absolute immune privilege of the CNS
has since been disputed with increasing evidence that the
brain is indeed subjected to immunological surveillance
(for review, see [32, 58]). However, there is clearly a
relative difference in immune privilege between the CNS
and peripheral tissues. The inflammatory response in the
CNS under pathological conditions propagates with a
different mechanism and in a different timeframe than that
in peripheral tissues [8]. Furthermore, the number of
immunological cells in the CNS is still greatly lower (if at
all present) compared to the periphery (T-lymphocytes
[82, 83, 196], B-lymphocytes [76, 77, 116]a n dm o n o c y t e s
[7, 8]).
The time course of BBB and BSCB breakdown in
multiple sclerosis [104], after traumatic brain injury [4, 87]
or SCI [41], has been reported to closely parallel the
progression of neuroinflammation. The accumulation of
immunological cells in perivascular spaces where basement
membrane and astrocytic foot processes were displaced
after SCI [182] suggests that BSCB breakdown may be
476 Transl. Stroke Res. (2011) 2:474–491involved in the expansion of the post-injury inflammatory
response after SCI.
Breakdown of the BSCB After SCI
The conceptual integration of the nervous and vascular
system is essential in understanding the pathophysiology of
SCI and provides a basis for potential intervention
strategies aimed at both nervous and vascular systems. In
addition to the death of endothelial cells, there is extensive
breakdown of the BSCB after SCI [17, 99, 102, 136, 147,
154, 159]. The lack of such a barrier protecting the spinal
cord allows for the indiscriminate passage of cellular toxic
molecules such as calcium [89, 164], excitatory amino
acids [127, 198], free radicals [131], erythrocytes [5, 64,
89, 99, 145, 147, 184] and inflammatory mediators [41]
into the injury penumbra, all of which may contribute to
secondary injury after SCI. Although BSCB dysfunction
has been reported largely from 2 [17, 99, 147, 154]t o
4 weeks post-injury [136], chronic abnormalities have been
observed at 8 weeks [182] and even 7 months post-injury
[159].
In animal studies, BSCB breakdown after SCI is
demonstrated by the extravasation of vascular tracers into
the spinal cord parenchyma. This has been reported as early
as 1 h post-injury and remains elevated for at least 24 h [64,
102, 147, 194]. This early peak in vascular leakage
coincides with the acute inflammatory response [41],
implicating the role of vascular permeability in the
propagation of the inflammatory response after SCI by
allowing inflammatory cells access into the injury penum-
bra. Increased BSCB permeability has also been observed
between 3 and 7 days post-injury [17, 99, 154, 182, 194,
204], correlating with the initiation of angiogenesis and
revascularization at the injury epicentre [25, 26, 42, 130,
194]. The destabilization of existing vessels by an increase
in vascular permeability is necessary for angiogenic
remodelling to occur and is evident as a breach of tight
junctions, displacement of astrocytic foot processes and
separation of the basement membrane [99, 147, 154]. In the
chronic phase of injury, up to 5.5 months, overlapping
endothelial cell junctions are reformed [99], although the
perivascular space continues to expand, with mis-aligned
extracellular matrix, collagen layers and displaced astrocyt-
ic foot processes [99]. This suggests that despite endoge-
nous reparative efforts, there are chronic morphological
abnormalities in the BSCB after SCI.
Given the implications of vascular disruption on sec-
ondary injury, the mechanisms by which angiogenesis
occurs and the BSCB restored are particularly relevant to
the topic of how neuroprotection can be achieved in acute
SCI. In the next section, we will discuss the role of the
three angiogenic proteins—specifically angiopoietin 1,
angiopoietin 2 and angiogenin—in the regulation of
angiogenesis and the restoration of the BSCB after SCI.
Introduction to the Angiogenic Proteins
The angiopoietins are a family of growth factors that
promote angiogenesis (for review, see [11, 203]). Ang1 and
Ang2 are the best-characterized members of the angiopoie-
tin family and are essential for the induction, maturation
and maintenance of blood vessels. Angiogenin is a potent
endothelial mitogen and belongs to the RNase A superfam-
ily of ribonucleolytic proteins. It is also implicated in the
pathogenesis of amyotrophic lateral sclerosis (ALS).
Angiopoietin 1
Ang1 was isolated by Davis et al. in 1996 [39] as a ligand
for tyrosine kinase with Ig and endothelial growth factor
homology domains (Tie) 2 receptors, which are predomi-
nantly expressed on endothelial cells [43, 44]. Ang1 is a
498-amino acid glycoprotein with a dimeric weight of
approximately 70 kDa [39, 186]. The Ang1 protein consists
of three distinct domains: a short amino terminus which
forms a ring-like structure to super-cluster Ang1 homo-
dimers together [40], a coiled-coil domain which mediates
the formation of Ang1 homodimers via a disulphide bond at
Cys245 [40, 155] and the carboxyl terminus which is
homologous to the carboxyl terminus of fibrinogen, hence
it being named the fibrinogen-like domain [40, 155]. This
domain is responsible for ligand activity [155] and contains
the binding site to Tie2 [40, 49].
Ang1 is constitutively expressed at a low basal level in
quiescent adult vasculature [39, 107, 132, 195, 197]b y
perivascular mural cells such as pericytes [181] and smooth
muscle [107, 133]. Upon activation of its receptor Tie2,
Ang1 induces pro-survival/anti-apoptotic effects on endo-
thelial cells [28, 119, 150, 151]. Ang1 binding induces
auto-phosphorylation of Tie2, which activates downstream
phosphatidylinositol 3-kinase (PI3K) and Akt [107, 151].
This has numerous downstream pro-survival effects, in-
cluding the upregulation of survivin [35, 37, 70, 151],
mammalian target of rapamycin [2] and the inhibition of
caspases 3, 7, 9, BCL2 antagonist of cell death, mitochon-
drial second mitochondria-derived activator of caspase [27,
70, 151] and Forkhead box protein O1 [37]. Ang1 has been
shown to interact with integrin to promote survival through
a similar activation of Akt as well as various mitogenic
protein kinases [35, 36]. Ang1 also modulates other
survival signals such as extracellular signal-regulated
kinase 1/2 (ERK1/2) [2, 71], stress-activated protein kinase
(SAPK) and c-Jun NH2-terminal kinase (JNK) [71].
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endothelial cell survival, Ang1 is crucial in maintaining
vessel quiescence by limiting vascular permeability and
controlling BSCB integrity [197]. Ang1 strengthens para-
cellular interactions and reduces the number and size of
endothelial gaps [12] by inducing the expression of
adhesive PECAM-1 [59] and tight junction proteins
occludin [88] and ZO-2 [126]. Ang1 further reinforces
vessel integrity by inhibiting the transcription of genes
associated with vessel destabilization and remodelling [37].
By securing paracellular junctions, Ang1 effectively limits
the progression the inflammatory response by restricting the
passage of inflammatory cells from the bloodstream to CNS
tissue [57]. Moreover, Ang1 activation of PI3K and Akt
[110, 111] inhibits the expression of inflammatory cytokine
nuclear factor-κB (NFκB) [96] and adhesion molecules
intercellular adhesion molecule 1, vascular cell adhesion
molecule 1 and E-selectin [59, 110], which are required for
the migration of inflammatory cells.
Although Ang1 has little to no proliferative effects on
endothelial cells [52, 117, 195], it is essential in the later
stages of angiogenesis, including the migration and orga-
nization of vessel components into mature, stable vessels
[197]. Ang1 promotes the migration of vascular compo-
nents to sites of angiogenesis [2, 24, 52, 53, 72, 106, 162,
195] and the organization of these components into tubule-
like structures.
It is hypothesized that the ability of Ang1 signalling to
both maintain the vasculature in a quiescent state as well as
mediate angiogenesis may be attributed to differential
ligand–receptor complexes that Ang1 and Tie2 receptors
form in mobile versus confluent cells [53, 162, 205]. In
mobile endothelial cells, Ang1 associates and binds to the
extracellular matrix [200] via β1-integrin [125] and releases
adhesion molecules which promote cell motility and
migration of vessel components [53, 162]. In contrast,
when associated with confluent, mature endothelial cells,
Ang1 mediates the formation of trans-associated Tie2
homotypic paracellular complexes to reinforce vascular
integrity [53, 162, 205].
Angiopoietin 2
Ang2 was first characterized in 1997 by Maisonpierre as
the natural antagonist of Ang1 [132]. Whilst Ang1 is
expressed at low basal levels constitutively, Ang2 expres-
sion is more actively regulated to modify and counteract
Ang1 signalling. Ang1 and Ang2 share approximately 60%
homology in their amino acid sequence, as well as a
common protein structure consisting of an amino terminal
that modulates super-clustering, a coiled-coil domain for
the formation of homodimers and a fibrinogen-like domain
with ligand activity [16, 40, 132]. Ang1 and Ang2 bind to
the same domain on Tie2 with similar affinities [15, 16,
132] and conformation [49]. However, they have opposite
effects on receptor phosphorylation and activation.
Whilst binding of Ang1 to Tie2 induces receptor auto-
phosphorylation and triggers downstream intracellular
signalling pathways, the binding of Ang2 does not [155].
The differential effects that Ang1 and Ang2 have on
receptor activation have been hypothesized to be due to
their different abilities to form homotypic oligomers. Native
Ang1 is largely found in superclusters of tetramers or
higher order oligomers, whereas Ang2 is predominantly
reported as homodimers [113, 155]. Receptor tyrosine
kinases such as Tie2 have been reported to require multi-
merization for receptor activation [113, 155]. Thus, it is
conceivable that although Ang2 dimers are able to bind to
Tie2 receptors, they may not be sufficient to elicit receptor
auto-phosphorylation, effectively acting as an antagonist for
Tie2. Interestingly, Ang2 is able to elicit agonistic effects
when driven outside of its natural physiological state, such
as at high concentrations, after prolonged exposure, as
engineered high-order oligomers or in non-endothelial cells
transfected with Tie2 [38, 40, 69, 108], supporting the
hypothesis that the antagonistic role of Ang2 in its
physiological state is at least in part mediated by its natural
tendency to form lower order oligomers.
Ang2 is expressed by endothelial cells [195]a n d
perivascular smooth muscle [133] at sites of active
angiogenesis during the vessel destabilization process [38,
132, 178]. Its expression is induced by hypoxia [132, 133,
153], hypoxic factor HIF1α [202] and vascular endothelial
growth factor (VEGF) [148]. Ang2 is stored in intracellular
Weibel–Palade bodies in endothelial cells along with von
Willebrand factor, which is involved in haemostasis [50].
Stored Ang2 has a half-life of 18 h but can be secreted
within minutes of stimulation [50]. In adults, Ang2
secretion is induced by various cytokines such as VEGF
and basic fibroblast growth factor [133], inflammatory
mediators tumour necrosis factor α and NFκB[ 109]o r
vasoactive molecule thrombin [50]. As the antagonist of
Ang1, Ang2 induces the destabilization of vessel integrity
[129, 148, 165], thus increasing BSCB permeability, but
also thereby allowing vessels to undergo remodelling.
Destabilization of existing vessels increases endothelial
plasticity and is a primary prerequisite to vascular
remodelling.
However, the result of these permeability changes also
depends on the local cytokine milieu. In the presence of
VEGF, Ang2 induces angiogenic sprouting, whilst in the
absence of VEGF, Ang2 destabilization leads to vessel
regression [18, 19, 86, 129]. Finally, Ang2 mediates the
escalation of the inflammation response by increasing
BSCB permeability to prime the endothelium and allow
the passage of inflammatory cells through the vessel [19,
478 Transl. Stroke Res. (2011) 2:474–49151]. By loosening endothelial cell junctions, Ang2 facili-
tates the migration of inflammatory cells from the blood-
stream into peripheral tissue [51, 109].
Angiogenin
Angiogenin is a 123-amino acid, 14-kDa protein that
potently induces angiogenesis and neovascularisation [48,
115, 142, 115, 187]. It was the first reported tumour-
derived angiogenic protein, characterized by Fett et al. in
1985 [48, 179]. Angiogenin shares 65% homology to
bovine pancreatic ribonuclease A [118, 179]. And although
it has surprisingly low ribonucleolytic activity [3], the
ribonucleolytic site on angiogenin appears to be essential
for its angiogenic actions [33, 34, 93, 142, 172, 173].
Angiogenin is predominately expressed and released by
endothelial cells, but it is also widely expressed by a variety
of anchorage-dependent proliferating cells including aortic
smooth muscle cells, fibroblasts and various tumour cells
[139]. Angiogenin expression is induced by HIF1α under
cellular stress or hypoxic conditions [74, 144, 168]. A 170-
kDa receptor has been identified as the angiogenin receptor
[94]. Upon binding, angiogenin is translocated to the
nucleus where it regulates genes controlling the prolifera-
tion of endothelial cells by activation of ERK [128], Akt
[114] and the SAPK/JNK pathways [201]. Angiogenin has
also been reported to interact with 42-kDa smooth muscle
type α-actin [91, 92]. This induces the formation of
angiogenin–actin complexes, which drive the degradation
the extracellular matrix and basement membrane of blood
vessels in order to promote the migration of vascular
components [90, 93].
Aside from its prominent role in promoting tumour
angiogenesis [48, 84, 115, 138, 139], angiogenin is well-
characterized in the pathogenesis of ALS. Genetic muta-
tions in angiogenin have been linked to both familial and
sporadic ALS [30, 62, 105]. These ALS-associated mutants
appear to have reduced or abolished survival-promoting
activity, leading to the degeneration of motor neurons, an
apparent symptom in the pathogenesis of ALS [168, 180,
199].
Angiogenic Proteins as Treatment after SCI
Vascular disruption, ischemia and BSCB permeability all
contribute to secondary injury after SCI. Therefore,
understanding angiogenesis and manipulating it therapeuti-
cally may potentially restore perfusion, reduce ischemic
insults and reconstitute the BSCB to ultimately limiting
secondary injury. Indeed, Ang1 as a treatment resulted in
improved functional and histological outcomes following
experimental SCI [67, 81]. Ang1 with the integrin-binding
peptide C16 was shown to rescue vasculature at the injury
epicentre [67]. There was also an increased amount of
spared white matter at both 7 and 42 days post-injury [67],
although no further improvement was observed at 42 than
7 days. Decreased inflammation was observed as early as
24 h post-injury, suggesting that targeting early mecha-
nisms such as vascular dysfunction can indeed result in
long-term functional improvements by rescuing vasculature
and reducing some aspects of inflammation very soon after
SCI. This study is of particular clinical importance, as
treatment did not begin until 4 h post-injury, which is a
clinically realistic timeframe for a neuroprotective inter-
vention in human SCI [67].
In another study, the combination of Ang1 and VEGF
treatment by AAV viral transfection immediately after SCI
decreased lesion volume and promoted vascular stability
[81]. The treatment decreased oedema, demyelination and
BSCB permeability, resulting in improved open-field
locomotor function at 56 days post-injury [81]. Interesting-
ly, the combination of Ang1 and other angiogenic mole-
cules such as C16 or VEGF both resulted in synergistic
functional outcome compared to each individual treatment,
suggesting that in addition to the promotion of angiogen-
esis, the roles of Ang1 in the formation of stable vessel and
regulation of BSCB permeability are crucial in limiting
secondary injury after SCI.
Whilst there has been extensive investigation of
angiogenic proteins as treatment after SCI, the endog-
enous expression of these proteins remains largely
elusive. One recent report examined changes in several
angiogenic growth factors in a rodent SCI model and
reported both prolonged (VEGF) and transient (Ang1,
PDGF, PlGF) decreases in gene expression up to
4 weeks post-injury [160]. However, the role that these
endogenous changes have in the angiogenic response to
SCI remains elusive.
Changes in Angiogenic Proteins After Acute Human
SCI
The discussion to this point has revolved around what has
been studied and reported with respect to Ang1, Ang2 and
angiogenin in animal models of SCI. The vast majority of
our scientific understanding of the pathophysiology of
secondary injury is derived from such animal studies.
However, therapies that have been shown to be effective
in rodent models of SCI have historically been unsuccessful
at demonstrating efficacy when translated to human clinical
trials. Whilst there are many potential reasons for this, one
is that important biological differences may exist between
the pathophysiology of such animal models and that of the
human condition.
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considerably more difficult than in animal models given
that cord specimens can only be obtained postmortem.
Our studies have therefore utilized what might be
considered ‘the next best thing’—cerebrospinal fluid
(CSF). We recognize that this is an indirect measure of
what is happening within the spinal cord itself and that
it would be challenging to interpret data from human
C S Fi nr e l a t i o nt ow h e nt h ep r o t e i n sa r ea c t u a l l yb e i n g
released or extruded from the injury site. However,
animal studies that have compared parenchymal and
CSF levels of specific molecules have shown that they
do correspond, albeit with much lower levels in the
CSF than the cord parenchyma [73, 193]. In this present
study, we investigated the temporal changes in three
angiogenic proteins: Ang1, Ang2 and angiogenin follow-
ing acute human SCI. We evaluated the protein levels in
both CSF and serum samples of SCI patients and non-SCI
controls. We sought to characterize the patterns of
expression of these proteins and how their levels might
be influenced by injury severity and/or hold implications
for neurological recovery after SCI.
Materials and Methods
Patients from a single level 1 regional trauma institu-
tion were enrolled in a clinical trial in which lumbar
intrathecal catheters were inserted to measure CSF
pressure and obtain CSF samples [121]. The clinical
trial protocol was approved by the university human
ethics committee and was registered on ClinicalTrials.gov
(ID: NCT00135278). Inclusion criteria for enrolment
included (1) SCI between C3 and T11 inclusive; (2)
ASIA impairment score (AIS) A—motor and sensory
complete SCI, B—motor complete, sensory incomplete
S C Io rC —motor and sensory incomplete SCI upon
presentation; (3) presentation within 48 h of injury and
(4) ability to provide a valid and reliable baseline
neurological exam. Patients with concomitant head
injuries, major trauma to the chest, pelvis or extremities
that required invasive intervention and those who were
too sedated or intoxicated to give a valid neurologic
examination were excluded. The patients provided in-
formed consent to participate in the study in which an
intrathecal drain was installed and left in situ for 3 to
5 days. To obtain control CSF from the ‘non-SCI’
condition, a direct lumbar dural puncture was performed
in individuals undergoing lumbar spine surgery.
Upon presentation, patients were evaluated by a clinical
research nurse, and a neurological examination was
performed to assign a baseline AIS and ASIA motor score.
Long-term outcome was measured at 6 months and 1 year
post-injury with parameters used in the initial baseline
neurological testing including AIS, ASIA motor score and
the last normal sensory level.
Intrathecal catheters (PERIFIX® Custom Epidural An-
aesthesia Kit; B. Braun Medical Inc., Bethlehem, PA, USA)
were inserted at L2/3 or L3/4, and 3 to 4 ml of CSF was
collected every 6 to 8 h for 3 to 5 days using a strict aseptic
technique. For non-SCI controls undergoing lumbar spine
surgery, a sample of CSF was obtained via needle puncture
of the dura at the end of their surgery. Samples were
immediately centrifuged at 1,000 rcf for 10 min. The
supernatant was aliquoted, snap-frozen in an ethanol and
dry ice bath and stored at −80°C until analysis. Blood
samples were drawn in both SCI patients and non-SCI
controls at the same times that CSF samples were collected.
The blood samples were left to clot at room temperature for
15 min and then centrifuged at 10,000 rcf for 5 min. The
serum was aliquoted, frozen and stored at −80°C until
analysis.
The CSF and serum samples were analysed using standard
quantitative sandwich ELISA kits for Ang1 (Quantikine®
Human Angiopoietin-1) and Ang2 (Quantikine® Human
Angiopoietin-2) and a microparticle-based multiplex
ELISA kit for Angiogenin (Fluorokine® MAP Human
Angiogenesis Base Kit A and Angiogenin bead set).
All kits were manufactured by R&D Systems Inc.,
Minneapolis, MN, USA. For SCI patients, up to 15
CSF and blood samples taken between 8 and 120 h
post-injury were analysed. A single baseline sample
was analysed for non-SCI controls. All samples were
r u ni nd u p l i c a t e .
Statistical analysis was performed using SPSS Statistics
17.0 software. Normal distribution in the data was tested
using the Shapiro–Wilk test, and equality of variances
between groups was tested using the Levene test. Kruskal–
Wallis H test was used to compare protein levels with
baseline AIS. The Friedman test was used to examine
temporal changes in individual patients. The Mann–
Whitney U test was used to compare values between SCI
patients and non-SCI controls at each time point. Spear-
man’s correlation was used to investigate relationships
between protein levels and outcome parameters at 6 months
or 1 year post-injury.
Results
For this study, we analysed 15 SCI patients equally
divided amongst injury severity, with five AIS A, five
AIS B and five AIS C at baseline (Table 1). Twelve
individuals suffered cervical SCI, whilst three suffered
thoracic SCI. The average age was 41.7 years, with 13
males and two females. Five patients were injured by
motor vehicle accidents, five during sporting activities,
four from falls and one resulting from a direct blow to the
480 Transl. Stroke Res. (2011) 2:474–491back of the head (Table 1). The CSF and serum of these 15
patients were compared against eight ‘non-injured’ control
subjects. This population averaged 60.1 years in age and
included four males and four females (Table 2).
The concentrations of Ang1, Ang2 and angiogenin
were evaluated at 12-h intervals from 24 h to 5 days
post-injury (Figs. 1, 2 and 3). The values within groups
did not display normal distribution (Shapiro–Wilk test),
and variances between groups were unequal (Levene
test); hence, non-parametric statistical tests were used for
all comparisons. No significant differences in Ang1,
Ang2 or angiogenin concentrations were found between
AIS A, B or C patients at any time point post-injury
(including baseline). Thus, the data from all injury
severities were pooled to compare the SCI condition
(AIS A, B and C) against non-SCI controls. For the non-
SCI controls, only a single CSF and serum sample was
obtained, and we made the assumption that the concen-
trations would remain largely unchanged over time in
these individuals.
For Ang1, both the CSF and serum levels of Ang1 at
the earliest time point were analysed, around 24 h post-
injury (p<0.05, Mann–Whitney U test) (Fig. 1). The
median Ang1 value in CSF in SCI patients at this time was
50.03 pg/ml [interquartile range (IQR) 43.70–84.19],
whereas the median value for non-SCI controls was
39.72 pg/ml [IQR 35.54–48.31]. In the serum, the median
value for SCI patients was 4,661.70 pg/ml [IQR 3,959.77–
Table 1 Demographics of SCI patients enrolled in the current study
Subject Age/
sex
Injury
level
Mechanism of injury Upon presentation 6-month or 1-year follow-up
AIS ASIA motor
score
Last normal sensory
level
AIS ASIA motor
score
Last normal sensory
level
SCI 1 42/M C6–7 Transport B 19 C5 B 27 C6
SCI 2 64/F C5–6 Sports C 41 C5 D 98 C2
SCI 3 66/M C4–5 Fall C 20 T9 C
a 49
a C4
a
SCI 4 60/M C4–5 Fall B 6 C5 D 80 C4
SCI 5 46/M C4–5–6 Transport C 5 C2 C
a 71 C5
SCI 6 20/M C6–7 Transport B 30 C6 C
a 86
a T6
a
SCI 7 39/M C3–4 Sports C 33 C3 D 83 C4
a
SCI 8 54/M C5–6 Transport C 36 C4 D
a 65
a C5
a
SCI 9 19/F T10 Fall A 50 T9 A 50 T7
SCI 10 38/M C5 Struck on the back of
head
B1 7 C 5 D
a 15
a C6
a
SCI 11 22/M L1 Transport A 60 C2 A
a 66
a L2
a
SCI 12 25/M C7 Sports A 43 C7 C 58 C7
a
SCI 13 51/M T10 Fall A 50 T11 A
a 50
a T11
a
SCI 14 55/M C6–7 Sports A 27 C6 UNK UNK UNK
SCI 15 25/M C5 Sports B 13 C4 B
a UNK C4
a
UNK unknown, where follow-up neurological testing was not performed or has not yet been performed at the time this manuscript was prepared
aSix-month follow-up
Table 2 Demographics of non-
SCI controls enrolled in the
current study
Subject Age/sex Diagnosis
CTRL 1 49/M L4–5 recurrent disc herniation
CTRL 2 85/F L2–3, 3–4, 4–5, 5–S1 stenosis
CTRL 3 52/F Right S1 radiculopathy
CTRL 4 68/F Degenerative L3–4 spondylolisthesis
CTRL 5 45/M L5–S1 disc herniation
CTRL 6 61/F L5–6 disc herniation
CTRL 7 62/M L5–S1 degenerative disc disease with neural foraminal stenosis
CTRL 8 59/M L3–4 spinal stenosis; L4–5 degenerative spondylolisthesis
Transl. Stroke Res. (2011) 2:474–491 4816,226.92] and 2,542.25 pg/ml [IQR 2,426.67–3,306.99] in
non-SCI controls. These elevations in Ang1 diminished
over the subsequent 12 h, and by 36 h post-injury, SCI and
control levels were no longer significantly different in
CSF or serum. There were also no statistically significant
correlations between Ang1 levels and the 6- and 12-month
neurologic outcomes.
In contrast to the early peak in Ang1, a delayed and
prolonged increase in CSF Ang2 expression was observed
(Fig. 2). Increased Ang2 levels were observed in SCI
patient CSF from 36 h post-injury and stay upregulated
until the end of the study period. The maximal difference in
CSF between SCI patients and non-SCI controls is
observed at 36 h post-injury, with SCI patient median at
599.16 pg/ml [IQR 394.19–688.38] and non-SCI control
median at 344.80 pg/ml [IQR 280.05–392.72]. The maxi-
mal difference in serum levels is observed at 60 h post-
injury, with SCI patient median at 2,685.61 pg/ml [IQR
1,588.76–3,823.93] and non-SCI control median at
1,358.77 pg/ml [IQR 1,207.85–2,080.15]. The differences
between SCI and non-SCI values were statistically signif-
icant in CSF from 36 h until the end of the study and in
serum between 48 and 60 h post-injury (p<0.05, Mann–
Whitney U test). Again, no significant correlations were
found between Ang2 values and the neurologic outcome at
6 months or 1 year post-injury.
For angiogenin within the CSF, the concentration in SCI
patients appeared to decrease starting around 36 h post-
injury, and between 72 and 84 h post-injury, levels were
significantly lower than in non-SCI controls (p<0.05,
Mann–Whitney U test) (Fig. 3). Maximal difference is
observed at 72 h post-injury with median value for SCI at
6.73 ng/ml [IQR 5.27–7.46] and median value for non-SCI
controls at 8.81 ng/ml [IQR 8.45–10.32]. In the serum,
there appear to be no changes until 60 h post-injury, with an
increasing trend from 60 to 120 h post-injury. Median
serum value for SCI at 120 h post-injury was 465.17 ng/ml
[IQR 402.77–631.82], and non-SCI median was 232.18
[IQR 204.11–316.50]. However, these values were not
significantly different between SCI and non-SCI controls
(p<0.05, Mann–Whitney U test).
Fig. 1 Median Ang1 protein levels in CSF and serum after acute
human SCI. SCI patients showed significantly higher Ang1 values
than non-SCI controls in both CSF and serum at 24 h post-injury.
Median CSF value for SCI patients at 24 h post-injury was 50.03 pg/
ml whereas median value for non-SCI controls was 39.72 pg/ml.
Median serum value at 24 h post-injury for SCI patients was
4,661.70 pg/ml, and median value for non-SCI controls was
2,542.25 pg/ml. Blue lines (circles) represent CSF values and red
lines (triangles) represent serum values. SCI patients are represented
with solid lines, and non-SCI controls are represented with dotted
lines. Data presented as median±IQR. *p<0.05, Mann–Whitney U
test
Fig. 2 Median Ang2 protein levels in CSF and serum after acute
human SCI. SCI patients showed significantly higher Ang2 values
from 36 h post-injury until the end of the study period at 120 h post-
injury in the CSF. Serum samples from SCI patients were also
significantly higher than non-SCI controls between 48 and 60 h post-
injury. The peak in CSF at 36 h post-injury in SCI was 599.16 pg/ml
compared to 344.80 pg/ml in non-SCI controls. The peak in serum is
observed at 60 h post-injury, with SCI value at 2685.61 pg/ml and
non-SCI control value at 1,358.77 pg/ml. Blue lines (circles) represent
CSF values, and red lines (triangles) represent serum values. SCI
patients are represented with solid lines, and non-SCI controls are
represented with dotted lines. Data presented as median±IQR. *p<
0.05, Mann–Whitney U test
Fig. 3 Median angiogenin protein levels in CSF and serum after acute
human SCI. SCI patients showed significantly lower angiogenin
values in CSF between 72 and 84 h post-injury. No significant
differences were observed between SCI patients and non-SCI controls
in serum samples. Median CSF value in SCI patients at 72 h post-
injury was 6.73 ng/ml, and median for non-SCI controls was 8.81 ng/
ml. Blue lines (circles) represent CSF values, and red lines (triangles)
represent serum values. SCI patients are represented with solid lines,
and non-SCI controls are represented with dotted lines. Data presented
as median±IQR. *p<0.05, Mann–Whitney U test
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The expression of angiogenic and BSCB-integrity-
promoting proteins in the acute phase post-SCI could limit
the spread of secondary damage by tightening the inter-
actions between endothelial cells and mural cells to close
the paracellular junctions in vessel walls, therefore preserv-
ing the BSCB. This could also eliminate the extra-vascular
space which has been reported to become a conduit for
inflammatory cells invading the site of injury [182].
Furthermore, by preserving distal circulation in the over-
lapping vascular networks of the spinal cord, adequate
perfusion to the site of injury could be maintained. In an
attempt to investigate the role of angiogenesis in the acute
phase after SCI, we have previously measured the levels of
another potent angiogenic factor, VEGF, using a similar
biochemical assay but were not able to detect it at any
measurable levels in the CSF of the current series of acute
SCI patients [124].
A decrease in the expression of Ang1 mRNA has been
reported after acute SCI in rats from 6 h to 2 weeks post-
injury [160]. Ang1 activity early after SCI could help
preserve the integrity of the BSCB, which when compro-
mised promotes the invasion of inflammatory cells and
other toxic blood products into the injury penumbra [147,
154, 194]. Although a transient increase in Ang1 expres-
sion is observed at 24 h, this is likely due to the release of
Ang1 from damaged endothelial cells into the CSF as a
result of the initial mechanical impact. The absence of a
sustained increase in Ang1 levels within the CSF in the
current study supports the contention of investigators such
as Han et al. [67] and Herrera et al. [81] who administered
Ang1 in the hopes of increasing angiogenesis and restoring
the integrity of the BSCB after acute SCI. These authors
showed that Ang1 alone or in combination with another
angiogenic factor resulted in functional improvements after
experimental SCI [67, 81].
Conversely, the prolonged upregulation of Ang2 expres-
sion from 36 h post-injury observed in the current study
could exacerbate secondary injury by destabilizing endo-
thelial junctions to increase BSCB permeability. A delayed
angiogenic response after SCI has been reported in several
studies, ranging from 3 to 7 days [17, 99, 154, 182, 194,
204]. No further neurological changes were correlated to
the new angiogenic status in these studies, adding evidence
to support that although endogenous reparative response of
the damaged tissue and vasculature is observed after acute
SCI, these neovessels fail to integrate into a functional
neurovascular unit. Furthermore, it is likely that the
increase in BSCB permeability during the early stages of
injury, in addition to the lack of continued robust Ang1
response, contributes to the exacerbation of secondary
injury. Angiogenesis and the maintenance of the BSCB
after acute traumatic SCI is not only a neuroprotective
strategy—to preserve remaining neurons and glia and
prevent further cell death by ischemia—but blood vessels
also provide trophic support and a scaffold for both
endogenous and potential regeneration strategies [143].
However, along with stimulating angiogenesis, this
prominent increase in Ang2 after SCI may allow the
passage of deleterious inflammatory cells and cytokines,
as well as cytotoxic molecules into the injury penumbra,
exacerbating secondary injury. A marked inflammatory
response has been established from 3 to 7 days post-
injury [41, 154, 194], which coincides with revasculariza-
tion of the injury epicentre [25, 42, 130, 194]. The time
course of BSCB repair also closely parallels that of the
appearance of the glial scar [130]. It has recently been
reported that a subpopulation of pericytes, perhaps those
which proliferate during the first angiogenic stage but are
not integrated into a functional neurovascular unit, leave the
vessel wall, trans-differentiate to express fibroblast markers,
migrate into the lesion epicentre and are responsible for a
majority of the extracellular deposition of the glial scar
sealing the injury epicentre [61].
There is a significant decrease in the CSF expression of
angiogenin between SCI and non-SCI control groups from
72 to 84 h post-injury, substantial inter-individual variation
and statistical noise may mask any potential differences
between SCI patients and non-SCI controls. However, the
decreased expression of angiogenin after SCI suggests that
the angiogenic changes that occur in the acute phase post-
injury are not driven by the same mechanism as tumori-
genic angiogenesis that has been reported to be associated
with angiogenin [48, 84, 138].
The temporal changes examined in this study represent
the changes of all sample SCI patients compared to all non-
SCI controls. However, it has been reported that there is a
substantial variation in inter-individual protein expression
levels in CSF even in healthy individuals [167]. We too
observed considerable variation in our SCI patients and
uninjured controls. Certain patterns of change present after
SCI in our sample population could potentially have been
masked by this great inter-individual variation, as it would
be logistically impossible to acquire a non-SCI baseline
measure for each SCI patient enrolled in this study to use as
a comparison for their post-SCI expression values. How-
ever, a majority of the values recorded for our non-SCI
controls reflect the values of controls which have previ-
ously been reported (Table 3)[ 6, 29, 31, 68, 80, 84, 95, 98,
101, 103, 112, 138, 140, 141, 152, 157, 174, 192].
In the current study, all protein levels in serum were
considerably higher, by orders of magnitude, than in CSF.
However, the serum and CSF concentrations did not appear
to be changing in parallel, which suggests that the changes
seen in the CSF are indeed local CNS changes, and not a
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Author Study Population Serum (ng/ml) CSF (ng/ml)
Ang1
Pg Current study SCI (n=15) At 24 h post-injury: At 24 h post-injury:
4.66 [3.96–6.23] 50.03 [43.70–84.19]
Ctrl (n=8) 2.54 [2.43–3.31] 39.72 [35.54–48.31]
Joshi Clin Biochem. 2011 Multiple myeloma (n=62) 36.28 (19.8–44.0)
Ctrl (n=50) 37.05 (35.7–39.2)
Reed Kidney International. 2011 Autosomal dominant polycystic
kidney disease (n=71)
35.52±21.03
Choe Joint Bone Spine. 2010 Bencet’s disease (n=59) 284.5±101.2
Ctrl (n=65) 237.1±76.4
Han Hypertens Pregnancy. 2010 Preeclampsia (n=16) Plasma
12.65 (1.27–17.5)
Ctrl (n=29) 10.35 (1.43–31.89)
Karapinar Heart and Vessels. 2010 Hypertension (n=49) 26.95±11.63
Ctrl (n=21) 43.34±9.77
Anagnostopoulos Br J Haematol. 2007 Waldenstrom’s macroglobulinemia
(n=56)
18.4 (1.7–107.5)
Ctrl (n=30) 23.2 (0.1–45.9)
Ang2
Pg Current study SCI (n=15) At 60 h post-injury: At 36 h post-injury:
2.69 [1.59–3.82] 599.16 [394.19–688.38]
Ctrl (n=8) 1.36 [1.21–2.08] 344.80 [280.05–392.72]
Joshi Clin Biochem. 2011 Multiple myeloma (n=62) 4.45 (2.1–13.25)
Ctrl (n=50) 1.67 (0.25–3.45)
Reed Kidney International. 2011 Autosomal dominant polycystic
kidney disease (n=71)
2.35±0.96
Han Hypertens Pregnancy. 2010 Preeclampsia (n=16) Plasma
11.2 (2.3–21.9)
Ctrl (n=29) 3.9 (1.4–14.7)
Helfrich Clin Cancer Res. 2009 Melanoma (n=98) 2.03 [1.71–3.28]
Ctrl (n=82) 1.24 [0.93–1.57]
Moreau Amyotroph Lateral Scler. 2009 ALS (n=40) 86.75 [67–132]
Ctrl (n=40) 82.5 [30–147]
Anagnostopoulos Br J Haematol. 2007 Waldenstrom’s macroglobulinemia
(n=56)
2.6 (1.0–11.3)
Ctrl (n=30) 1.4 (0.6–5.1)
Angiogenin
Ng Current study SCI (n=15) At 120 h post-injury: At 72 h post-injury:
465.17 [402.77–631.82] 6.73 [5.27–7.46]
Ctrl (n=8) 232.18 [204.11–316.50] 8.81 [8.45–10.32]
Moreau Amyotroph Lateral Scler. 2009 ALS (n=40) 288.0 [267–307]
Ctrl (n=40) 282.5 [244–326]
Ilzecka Acta Clin Croat. 2008 ALS (n=20) 0.328 (0.208–0.45)
Ctrl (n=15) 0.286 (0.153–0.483)
Patel Ann Med. 2008 Chronic heart failure (n=109) 466 [314–739]
Ctrl (n=112) 310 [264–376]
Anagnostopoulos Br J Haematol. 2007 Waldenstrom’s macroglobulinemia
(n=56)
398.1 (147.4–1,180.6)
Ctrl (n=30) 226.9 (145.8–398.7)
Huang Eur Neurol. 2007 Acute cerebral infarction
(n=30)
At 48 h:
415.1±76.8
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This is evident in the changes seen in Ang2. Whilst Ang2
levels in the serum were much below that of Ang1, they
become substantially higher than Ang1 levels in CSF. This
is not unexpected, as Ang1 is constitutively expressed in
the maintenance of quiescent adult vessels, whilst Ang2 is
only found at sites of active angiogenesis. Given the
context of BSCB breakdown after SCI and the antagonistic
role of Ang2 against Ang1, this suggests that this increase
is indeed an active upregulation in the expression and/or
secretion of Ang2 locally, which may indicate the destabi-
lization of local vasculature and breakdown of BSCB after
SCI.
Much of the current knowledge regarding the
mechanisms of secondary injury has been deciphered
in animal models of SCI, whilst the direct observation
of human injuries is far less common. It is important to
keep in mind when examining animal studies that there
are considerable differences in both anatomy and
physiology between such animal models and human
injuries. For example, humans may be more susceptible
to spinal cord ischemia compared to rodents because of
the increased distance between segmental arteries that
are exclusively dependent on diffusion from the
capillary supply. Within the thoracic cord, anatomical
differences also exist, with a ‘watershed’ region of the
human thoracic cord dependent upon the ascending
lumbar artery (and thus vulnerable to ischemia) as
compared to the rodent thoracic cord which has
sufficient collateral supply. Furthermore, the develop-
ment of the progressive secondary injury is observably
different between species with regards to cavitations
and scarring. These differences may dampen the ability
to translate a potential therapeutic treatment into the
clinical setting. The reverse translation of information
gathered from clinical studies back to the controlled
environment of the laboratory could be crucial to
extract the differences that exist between animal models
and the clinical setting and accelerate the tedious
process of clinical translation of pharmaceutical inter-
ventions for the treatment of SCI.
In conclusion, this article summarizes a portion of the
published literature regarding the vascular injury that
occurs after SCI and presents novel findings on the
expression of three angiogenic proteins: Ang1, Ang2 and
angiogenin in CSF and serum after acute human SCI. The
intimate relationship of the neurovascular unit and its
pathophysiology remains an important focus as a neuro-
protective/neuroregenerative strategy for SCI and other
CNS disorders alike.
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Table 3 (continued)
Author Study Population Serum (ng/ml) CSF (ng/ml)
Ctrl (n=20) 334.9±93.9
Siebert Diabetes Care. 2007 Diabetes mellitus type 2
(n=43)
319.7±107.04
Ctrl (n=43) 550.54±187.99
Cronin Neurology. 2006 ALS (n=79) 396.7±120.9
Ctrl (n=72) 334.6±106
Kim Leukemia and Lymphoma. 2005 Leukaemia (n=43) 277.6 (145.9–533.7)
Ctrl (n=18) 226 (68–349.8)
Molica Eur J Haematol. 2004 Leukaemia (n=77) 295 (74–1,700)
Ctrl (n=15) 264 (29–1,835)
Hisai Clin Cancer Res. 2003 Hepatocellular carcinoma
(n=39)
362.3±84.1
Ctrl (n=31) 331.9±133.8
Verstovsek Br J Haematol. 2001 Leukaemia/myelodysplastic
syndrome (n=101)
Plasma
609.7 (127.6–1,054.0)
Ctrl (n=11) 197.1
Miyake Cancer. 1999 Urothelial carcinoma (n=135) 434.86±186.02
Ctrl (n=52) 337.5±71.4
Data shown as mean±SD and (range) or median and [IQR]. Control values are shown in italics
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